Top Performing Drug Developers Are Merging Operational and Strategic Objectives, According to Tufts Center for the Study of Drug Development
October 30, 2009 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - October 30, 2009) - Drug companies racing to develop new products to
replace drugs coming off patent are finding that success is increasingly
tied to the company's ability...
Marketing Exclusivity for First-in-Class Drugs Has Shortened to 2.5 Years, According to Tufts Center for the Study of Drug Development
September 09, 2009 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - September 9, 2009) - Marketing exclusivity periods for first-in-class
drugs have fallen dramatically in recent decades -- from a median of 10.2
years in the 1970s to 2.5...
Large Pharmaceutical Firms Are Getting More Drugs Into Development While Terminating Unpromising Candidates, According to Tufts Center for the Study of Drug Development
July 22, 2009 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - July 22, 2009) - Large pharmaceutical firms, under pressure to
bring new medicines to market faster, have been getting more drug
candidates into development in recent years...
New Drug R&D Increasingly Depends on Partnerships Between Drug Sponsors and Service Providers, According to Tufts Center for the Study of Drug Development
July 08, 2009 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - July 8, 2009) - If drug developers are to remain competitive,
they must rely less on traditional outsourcing, in which external service
providers offer a way to quickly...
Number of Therapeutic Peptides in Clinical Study Has Nearly Doubled Since the 1990s, According to Tufts Center for the Study of Drug Development
May 20, 2009 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - May 20, 2009) - Since 2000, the number of therapeutic peptides
in clinical study has nearly doubled the 1990s rate, due in part to
advances in synthesis, delivery, and...
NineSigma Report Benchmarks State of Open Innovation
April 29, 2009 16:46 ET
|
NineSigma, Inc.
CLEVELAND, OH--(Marketwire - April 29, 2009) - NineSigma, the leading provider of open innovation
solutions, today released the results of its first open innovation (OI)
study that establishes a...
Pharmaceutical Licensing Success Is Tied to Clarity of Strategy on Both Sides, According to Tufts Center for the Study of Drug Development
April 16, 2009 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - April 16, 2009) - Pharmaceutical firms looking to license new drug
candidates from other firms will improve their chances of achieving a
successful alliance if they focus on...
NineSigma and KnowledgeWorks Partnership Expands Open Innovation in South Korea
March 31, 2009 10:48 ET
|
NineSigma, Inc.
CLEVELAND, OH--(Marketwire - March 31, 2009) - NineSigma, the leading provider of open innovation
solutions, today announced a strategic partnership between its Asian
company, NineSigma Japan, Inc.,...
Three-Quarters of U.S. Health Plans Reimburse for Off-Label Uses of Prescription Drugs, According to Tufts Center for the Study of Drug Development
March 10, 2009 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - March 10, 2009) - Reflecting recent rapid growth of off-label
prescribing of prescription drugs, 75 percent of all health plans in the
United States now reimburse patients...
Drug Developers Looking to Learn as Much as Possible in Phase I Trials, According to Tufts Center for the Study of Drug Development
January 27, 2009 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 27, 2009) - Under pressure to develop new medicines more
quickly and at lower cost, drug sponsors are looking to answer as many
questions as possible in Phase I,...